argenx SE (ARGX) Balance Sheet

This trajectory signals a fundamental shift in business quality, moving from a capital-dependent startup to a self-funding commercial powerhouse. The primary driver is the conversion of operating profits into a massive cash reserve, which now constitutes 36% of total assets, providing immense strategic flexibility for pipeline expansion or potential M&A without dilutive financing.

The current ratio, while declining from a peak of 11.07 in Q2 2022, remains exceptionally high and suggests the company can comfortably meet all near-term obligations. This substantial cash buffer insulates the company from capital market volatility and allows management to pursue its 'pipeline-in-a-product' strategy without financial constraint.

This inflection from a cumulative deficit of over $2 billion just two years prior demonstrates the powerful cash-generative nature of the VYVGART franchise. It suggests the company is now building intrinsic equity value through operations rather than relying on external capital raises, which fundamentally alters its risk profile and capital allocation options.

The relatively low PPE base indicates argenx operates an asset-light model, likely relying on contract manufacturing organizations (CMOs) for biologic production. The goodwill balance, which has grown from $9.4M in Q2 2024 to $266M in Q2 2026, suggests recent acquisitions or technology licenses, warranting monitoring for potential impairment risk if pipeline assets underperform.